Literature DB >> 15465553

Involution of threshold retinopathy of prematurity after diode laser photocoagulation.

David K Coats1, Aaron M Miller, Kathryn M Brady McCreery, Eric R Holz, Evelyn A Paysse.   

Abstract

OBJECTIVE: To characterize the process of involution of threshold retinopathy of prematurity after transpupillary diode laser photocoagulation.
DESIGN: Retrospective case series. PARTICIPANTS: Neonates with threshold retinopathy who underwent diode laser photocoagulation of the peripheral avascular retina.
METHODS: A retrospective chart review was done of the weekly examination records of infants treated for threshold disease. Features that were studied included the presence of residual stage 3 neovascularization, plus disease, and development of retinal detachment (RD). MAIN OUTCOME MEASURES: Timing of full involution and/or development of an RD.
RESULTS: Of 262 eyes of 138 infants treated, full involution without RD was seen in 8%, 43%, 64%, 73%, and 86% of eyes at postoperative weeks 1, 2, 3, 4, and 9+/-3, respectively. Retinal detachments were diagnosed cumulatively in 0%, 1.5%, 4.2%, 6.5%, and 14% of eyes at weeks 1, 2, 3, 4, and 9+/-3, respectively.
CONCLUSIONS: Full involution of laser-treated threshold retinopathy of prematurity required more than 2 weeks in more than half of treated eyes. Most RDs were not detected until > or =3 weeks after treatment.

Entities:  

Mesh:

Year:  2004        PMID: 15465553     DOI: 10.1016/j.ophtha.2004.02.005

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  8 in total

1.  Recombinant alpha2(IV)NC1 domain of type IV collagen is an effective regulator of retinal capillary endothelial cell proliferation and inhibits pre-retinal neovascularisation.

Authors:  Gary Coleman; Tom A Gardiner; Ariel Boutaud; Alan W Stitt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-08-17       Impact factor: 3.117

2.  Fibrovascular organization in the vitreous following laser for ROP: implications for prognosis.

Authors:  M Elizabeth Hartnett; Janet R McColm
Journal:  Retina       Date:  2006-09       Impact factor: 4.256

3.  Retinopathy of prematurity: involution, factors predisposing to retinal detachment, and expected utility of preemptive surgical reintervention.

Authors:  David K Coats
Journal:  Trans Am Ophthalmol Soc       Date:  2005

4.  Involution patterns of retinopathy of prematurity after treatment with intravitreal bevacizumab: implications for follow-up.

Authors:  M Isaac; N Tehrani; K Mireskandari
Journal:  Eye (Lond)       Date:  2016-02-12       Impact factor: 3.775

5.  Refractive and Visual Outcome after Laser-Treated Retinopathy of Prematurity in Western Romania.

Authors:  Florina Stoica; Corina Ladariu; Marie-Jeanne Koos; Alina Stanciu; Gabriela Olariu; Nicoleta Andreescu; Maria Puiu
Journal:  Maedica (Buchar)       Date:  2016-06

Review 6.  Description and management of retinopathy of prematurity reactivation after intravitreal antivascular endothelial growth factor therapy.

Authors:  Nita G Valikodath; Michael F Chiang; R V Paul Chan
Journal:  Curr Opin Ophthalmol       Date:  2021-09-01       Impact factor: 4.299

7.  Stanford University Network for Diagnosis of Retinopathy of Prematurity (SUNDROP): 18-month experience with telemedicine screening.

Authors:  Ruwan A Silva; Yohko Murakami; Atul Jain; Jarel Gandhi; Eleonora M Lad; Darius M Moshfeghi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-09-11       Impact factor: 3.117

8.  Favorable outcomes of adequate laser photocoagulation and salvage bevacizumab treatment for aggressive posterior retinopathy of prematurity.

Authors:  Yoko Fukushima; Takahiro Fujino; Shunji Kusaka; Yoshikazu Hatsukawa; Kohji Nishida
Journal:  Am J Ophthalmol Case Rep       Date:  2018-05-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.